doi: 10.1038/nrc3829 3 BallesterosJ
Tezspire, the TSLP inhibitor co-commercialised with Amgen for severe uncontrolled asthma, recorded combined worldwide sales of USD 843 million for the nine months to September 2024 growing rapidly as the first biologic targeting TSLP upstream of the inflammatory cascade
Elgendy, Abdalhakim Shubietah Endocrinology, Diabetes & Metabolism.2026;[Epub] CrossRef Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown Edoardo Mannucci, Ilaria Dicembrini Nature Reviews Clinical Oncology.2026
doi:10.1016/j.cbpc.2018.09.003
Weight loss tends to become steadier
[7,8] Beyond 6 weeks If a patient has had enough time at an effective dose with tolerable side effects and reasonable adherence, but still shows weak response, it becomes more reasonable to think about genuine low responsiveness, type 2 diabetes-related attenuation of weight-loss effect, or whether another agent may be better
